Anne L Angiolillo
Children's Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anne L Angiolillo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:39 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT01190930 · Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaChildren's Oncology Group · completed · Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma · principal investigator
- Ph3NCT00671034 · Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic LeukemiaChildren's Oncology Group · completed · Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- AN INTERNATIONAL, RANDOMIZED, CONTROLLED TRIAL OF IMMUNE-TOLERANCE INDUCTIONM01RR020359 · NCRR · CHILDREN'S RESEARCH INSTITUTE · fiscal years 2005 · $3,882 awarded in 2005Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Children's Oncology Group Chair's GrantU10CA098543 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI PETER C. ADAMSON · fiscal years 2003 to 2013Named on NCT01190930, NCT00671034
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT01190930
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:39 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.Blood · 2017251 citationsRCR 8.2
- 211 citationsRCR 5.4
- 207 citationsRCR 51.1
- 107 citationsRCR 3.5
- 93 citationsRCR 5.8
- A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.Pediatr Blood Cancer · 200970 citationsRCR 1.6
- Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.Leuk Lymphoma · 201940 citationsRCR 1.9
- Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children's Oncology Group Report.Pediatr Blood Cancer · 200619 citationsRCR 0.4